The installation of our new THC distillation unit marks a major milestone in bringing highly purified natural THC to market — with full pharmaceutical compliance.
Following changes in Swiss legislation in 2022, Linnea began to fully develop its capabilities to work with THC. Since then, our team has focused on establishing a dedicated production line that meets the highest pharmaceutical standards, consistent with the rest of the Linnea facility—starting with CO₂ supercritical extraction and now advancing into specialized distillation.
Linnea’s R&D has already developed a method to purify THC above 90% at industrial scale, and the distillation unit, now installed in our GMP-approved narcotics area, is the initial step. First R&D samples are expected by the end of the year, with pharma-grade material to follow.
From production to storage, Linnea’s quality system guarantees excellence at every step and also our highly purified natural THC will be:
- Manufactured in Switzerland from EU-origin Cannabis sativa L.
- Listed in the EU EudraGMP database
- Available with Drug Master File, ready for pharmacies, clinical trials, and registrations.
This is just the beginning — and we’re set to drive the change.
